When a chiral centre has to be set reliably, many process chemists still reach for an Evans auxiliary. 4-Phenyl-2-Oxazolidinone is one of the most widely used of these auxiliaries, and both of its enantiomers have become important again now that oral GLP-1 medicines...
Since the European Commission granted marketing authorisation to Lazcluze® (lazertinib) in January 2025, interest in its chemistry has grown steadily across Europe. For API developers, CDMOs and generic R&D teams, the first sourcing decision is always the same:...
Lazertinib Intermediate Supplier | CAS NO: 26033-20-5 Following the European Medicines Agency (EMA) marketing authorization of Lazcluze™ (Lazertinib) in combination with amivantamab for first-line treatment of adult patients with advanced EGFR-mutated non-small cell...
High-Purity Orforglipron Intermediates: Direct Manufacturing Partner for UK & Europe The authorization of Orforglipron (Foundayo™) by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in August 2026 marked a historic turning point in the European...
Lazertinib & Orforglipron Intermediates: Manufacturer & Supplier The global pharmaceutical landscape in 2026 is witnessing surging commercial demand for advanced small-molecule therapeutics. In the European Union and United Kingdom, two high-impact active...
The pharmaceutical and chemical industries rely on high-performance coupling reagents for peptide synthesis, drug development, and advanced organic chemistry. One of the most widely used reagents in these applications is EDC HCl, a highly effective carbodiimide-based...
Recent Comments